Skip to Main Content

An experimental pill from Vertex Pharmaceuticals reduced levels of a damaging urine protein by nearly half in a small clinical trial — encouraging evidence that a novel medicine can arrest the underlying genetic cause of a chronic kidney disease that progresses rapidly to kidney failure.

Vertex called the mid-stage study results “unprecedented” and said it was working quickly to advance the drug, called VX-147, into a pivotal clinical trial, pending discussions with regulators.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

Create a display name to comment

This name will appear with your comment